tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Replimune downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns downgraded Replimune (REPL) to Neutral from Buy without a price target after the FDA issued a complete response letter for RP1 in anti-PD1 failed melanoma patients. RP1’s path to market “just got painfully longer,” the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1